Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
企業コードACON
会社名Aclarion Inc
上場日Apr 22, 2022
最高経営責任者「CEO」Ness (Brent)
従業員数6
証券種類Ordinary Share
決算期末Apr 22
本社所在地8181 Arista Place
都市BROOMFIELD
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号80021
電話番号18332752266
ウェブサイトhttps://aclarion.com/
企業コードACON
上場日Apr 22, 2022
最高経営責任者「CEO」Ness (Brent)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし